Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 in refractory metastatic colorectal cancer
NCT01607957Phase 3Completed
- Sponsor
- Taiho Oncology
- Start
- Jun 2012
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in metastatic colorectal cancer (mCRC) comparing TAS-102 with Placebo (2 arms). Primary endpoint: Overall Survival up to 12 months. Started Jun 2012; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01607957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01607957.